樂
樂觀
樂觀 · 25%NVAX
$12.67
情境價格
$12.820
+0.182 (+1.42%)收盤時
Loading chart…
- 最高
- 13.250
- 開盤
- 12.500
- 成交量加權均價
- 12.76
- 成交量
- 7.36M
- 市值
- 1.89B
- 最低
- 12.200
- 成交金額
- 93.92M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- -9.00
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
AI 分析 of Novavax Inc (NVAX)
買進Novavax Inc is a good buy right now due to its recent price increase of 21.89% over the last 5 days and a current price of $12.75, which is significantly above its 200-day simple moving average of $9.015. The stock's RSI is at 71.683, indicating strong momentum, while the forward P/E ratio is an attractive 2.58, suggesting potential for future earnings growth. However, the main risk is its negative net income margin of -94.16% in Q2 2026, which highlights ongoing profitability challenges.
分析師評級（7）
-18.10% 下跌空間
持有
2 買進
5 持有
0 賣出
目前: 12.82
最低
6.00
平均
10.50
最高
18.00
BofA
落後大盤
$8
2026-10-09
BofA
2026-10-09
目標價
$8
落後大盤
TD Cowen
持有
$9
2026-05-06
TD Cowen
2026-05-06
目標價
$9
持有
B. Riley
買進
$18
2026-04-09
B. Riley
2026-04-09
目標價
$18
買進
BofA
落後大盤
$8
2026-02-27
BofA
2026-02-27
目標價
$8
落後大盤
H.C. Wainwright
買進
$16
2026-02-27
H.C. Wainwright
2026-02-27
目標價
$16
買進
估值指標
Novavax Inc（NVAX）目前預期本益比為 2.58，5 年平均預期本益比為 -3.89。
Alphio AI 對 NVAX 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
持有 NVAX 的大戶
事件時間軸
資訊
8.510-10stocktwitsNational Cancer Vaccine Initiative Launches
5.010-06CNBCGrail's Cancer Blood Test Approaches Regulatory Decision
2.010-06CNBCTech Stocks Volatility and Investment Outlook
2.010-06stocktwitsRussian Plague Scare Triggers Vaccine Stock Surge
4.510-06stocktwitsTech Stocks Surge, Nasdaq Hits All-Time High
NVAX 常見問題 —— 由 Alphio AI 解答
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Novavax Inc is a good buy right now due to its recent price increase of 21.89% over the last 5 days and a current price of $12.75, which is significantly above its 200-day simple moving average of $9.015. The stock's RSI is at 71.683, indicating strong momentum, while the forward P/E ratio is an attractive 2.58, suggesting potential for future earnings growth. However, the main risk is its negative net income margin of -94.16% in Q2 2026, which highlights ongoing profitability challenges.
7 analysts cover NVAX: 2 rate it Buy, 5 Hold and 0 Sell. The average price target is 10.50.
社群
更多 ↗
$NVAX The week ultimately closed with a fantastic weekly candle. You can see the nearest resistance levels on the chart. I am including the quarterly SMA20 because it is a key target to reach (it's a pity that it is in freefall, blame the math). Keep an eye on that weekly stochastic over the coming weeks. It looks good for now; let's hope it stays that way. GLTA (Warning: If you don't have a position here at this point, don't start one)
展開
$NVAX Early weekly chart just to show how the week started ... but what really matters is how the week ends. Three things: - The quarterly SMA20 that I mentioned in the prior post is now around 14.3x. - 61.80% fibo retracement was reached ( $13.14 ) - If we want a serious technical move this beast should respect any re-test of the long term resistance recently broken by turning it into support. Otherwise this would be another pump and dump. See you on weekend...
展開
$NVAX That short-term hypothesis was overruled, of course. For what it's worth, the daily RSI is in overbought territory and at its highest level in the last 2 years. If you want this sharp price action to keep going up, then the RSI needs to go wild from here (like in May-June 2024). Good luck to all.
展開
$NVAX Novavax, the maker of a protein-based COVID-19 vaccine, rose Monday as traders circulated claims of a Russian plague outbreak. A lab leak in Siberia sent one technician to the hospital last week, where she died from undetermined pneumonia. The numbers behind the move and what the market has to price next:
展開
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。